Diagnostic and Interventional Radiology
Interventional Radiology - Original Article

MR angiography-planned prostatic artery embolization for benign prostatic hyperplasia: single-center retrospective study in 56 patients


Institute of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, Frankfurt am Main, Germany


Department of Diagnostic and Interventional Radiology, Cairo University Hospital, Cairo, Egypt


Department of Radiology, AMEOS Hospital Halberstadt, Halberstadt, Germany


Department of Diagnostic and Interventional Radiology, Alexandria University Hospital, Alexandria, Egypt

Diagn Interv Radiol 2020; 1: -
Read: 116 Published: 09 October 2020

PURPOSE: To evaluate the advantages of MR angiography (MRA)-planned prostatic artery embolization (PAE) for benign prostatic hyperplasia (BPH). 

METHODS: In this retrospective study MRA’s of 56 patients (range: 47-82 years; mean: 67.23 ± 7.73 years) with a PAE between 2017 and 2018 were evaluated. For inclusion, full information about procedure time and radiation values must have been available.  To identify prostatic artery (PA) origin, 3-dimensional MRA reconstruction with maximum intensity projection was conducted in every patient.  33 patients did complete clinical and imaging follow up and were included in clinical evaluation. 


RESULTS: In total there were 131 PA’s with a second PA in 19 pelvic sides. PA origin was correctly identified via MRA in 108 of 131 PA’s (82.44%). In patients in which MRA allowed a PA analysis, a significant reduction of the fluoroscopy time (-27.0%, P = 0.028) and of the dose area product (-38.0%, P = 0.003) was detected versus those with no PA analysis prior to PAE. Intervention time was reduced by 13.2%, (p=0.25). Mean fluoroscopy time was 30.1 minutes, mean dose area product 27,749 µGym2 and mean entrance dose 1,553 mGy. Technical success was achieved in all 56 patients (100.0%); all patients were embolized on both pelvic sides. The evaluated data documented a significant reduction in IPSS (P < 0.001; mean 9.67 points). 


CONCLUSION: MRA prior to PAE allowed the identification of PA in 82.44% of the cases. MRA-planned PAE is an effective treatment for patients with BPH.


EISSN 1305-3612